CliffBio
biologic

Humate-P

Antihemophilic Factor/von Willebrand Factor Complex (Human)

Loss of exclusivityApril 2012projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameHumate-P
Active ingredientAntihemophilic Factor/von Willebrand Factor Complex (Human)
Strength250IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2000
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humate-P patent cliff — loss of exclusivity April 2012 | CliffBio